Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL4254570 | 0.92 | FAAH (0.44) | FAAHALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL3669028 | 0.86 | SIGMAR1 (0.51) | ALDH1A1MAPTNAAASIGMAR1HRH2 | |
| SCHEMBL2323553 | 0.86 | SIGMAR1 (0.51) | ALDH1A1MAPTNAAASIGMAR1HRH2 | |
| SCHEMBL5990174 | 0.85 | FAAH (0.52) | FAAHALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL5724530 | 0.84 | SIGMAR1 (0.50) | ALDH1A1NAAASIGMAR1HRH2HRH1 | |
| SCHEMBL19489977 | 0.83 | SIGMAR1 (0.49) | ALDH1A1NAAASIGMAR1HRH2HRH1 | |
| SCHEMBL11855822 | 0.81 | NAAA (0.60) | FAAHALDH1A1MAPTTHRBNAAA | |
| SCHEMBL27059753 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MAPTTHRBCNR1MGLL | |
| SCHEMBL21877921 | 0.80 | MGLL (0.45) | FAAHALDH1A1MAPTTHRBCNR1 | |
| SCHEMBL21877923 | 0.80 | MGLL (0.45) | FAAHALDH1A1MAPTTHRBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117301-A1 | USE OF LONG-CHAIN ALCOHOL DERIVATIVES FOR THE TREATMENT OF ALOPECIA AREATA | Yeda Research And Development Co. Ltd. At The Weizmann Institute of Science (IL) | 2009-11-18 | — | — | EP | claimed |
| US-20080221115-A1 | Use of long-chain alcohol derivatives for the treatment of alopecia areata | YEDA RESEARCH AND DEVELOPMENT CO. (IL) | 2008-09-11 | — | — | US | claimed |
| WO-2008106091-A1 | USE OF LONG-CHAIN ALCOHOL DERIVATIVES FOR THE TREATMENT OF ALOPECIA AREATA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2008-09-04 | — | — | WO | claimed |
| EP-2117301-A1 | USE OF LONG-CHAIN ALCOHOL DERIVATIVES FOR THE TREATMENT OF ALOPECIA AREATA | Yeda Research And Development Co. Ltd. At The Weizmann Institute of Science (IL) | 2009-11-18 | — | — | EP | disclosed |
| US-20080221115-A1 | Use of long-chain alcohol derivatives for the treatment of alopecia areata | YEDA RESEARCH AND DEVELOPMENT CO. (IL) | 2008-09-11 | — | — | US | disclosed |
| WO-2008106091-A1 | USE OF LONG-CHAIN ALCOHOL DERIVATIVES FOR THE TREATMENT OF ALOPECIA AREATA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221115-A1 | Use of long-chain alcohol derivatives for the treatment of alopecia areata | SLC38A7, CCR8, ADH1A | FAAH 646/4885ALDH1A1 364/4885MAPT 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.